Role of HHV‐8 and mTOR pathway in post‐transplant Kaposi sarcoma staging

A Hernández‐Sierra, J Rovira, A Petit… - Transplant …, 2016 - Wiley Online Library
A Hernández‐Sierra, J Rovira, A Petit, D Moya‐Rull, MA Mazuecos, AI Sánchez‐Fructuoso…
Transplant International, 2016Wiley Online Library
Kaposi's sarcoma (KS) is one of the most frequent transplant related tumors. Several
pathways are involved; however, the impact of the molecular phenotype associated to the
tumor stage and the behavior‐depending resultant therapy is still unknown. The aim of our
study was to analyze the role of HHV‐8 and mTOR pathway in tumor stages of skin KS after
renal transplantation. Twelve renal transplant recipients with cutaneous KS from five
transplant centers (1980–2007) under reduction of immunosuppression or conversion to …
Summary
Kaposi's sarcoma (KS) is one of the most frequent transplant related tumors. Several pathways are involved; however, the impact of the molecular phenotype associated to the tumor stage and the behavior‐depending resultant therapy is still unknown. The aim of our study was to analyze the role of HHV‐8 and mTOR pathway in tumor stages of skin KS after renal transplantation. Twelve renal transplant recipients with cutaneous KS from five transplant centers (1980–2007) under reduction of immunosuppression or conversion to mTOR inhibitor were included. The expression of HHV‐8, PTEN, TGFβ, VEGF, phospho‐mTOR, and phospho‐P70S6K in tumoral tissue was analyzed. KS lesions were classified as patch, plaque, and nodule state. HHV‐8 infection was found in all tissue samples. KS lesions showed high activation of VEGF, p‐mTOR and p‐P70S6K, low PTEN, and null TGFβ expression. The only pathway activated in a staging‐dependent manner was mTOR with higher p‐mTOR and p‐P70S6K expression in nodule versus patch stage. KS lesions disappeared after 5.24 months in all converted patients without any recurrence in 14.05 years of mean follow‐up. The activation of mTOR pathway according to KS stages supports the rational of the mTOR inhibitor in post‐transplant Kaposi.
Wiley Online Library